Wave Life Sciences reports positive interim Phase 1 data for WVE-007 showing 14.3% placebo-adjusted visceral fat reduction; FDA alignment for WVE-006

Wave Life Sciences reported positive interim Phase 1 data for WVE-007, an INHBE siRNA program for obesity, showing a 14.3% placebo-adjusted reduction in visceral fat at six months after a single 240 mg dose. The company initiated the Phase 2a portion of the INLIGHT trial and has a combination study with tirzepatide underway, and reported FDA alignment for WVE-006.

Detected & updated continuously · Source: Nebula